Wealthcare Advisory Partners LLC Takes $252,000 Position in Guardant Health, Inc. (NASDAQ:GH)

Wealthcare Advisory Partners LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 8,255 shares of the company's stock, valued at approximately $252,000.

A number of other hedge funds have also recently modified their holdings of GH. Lord Abbett & CO. LLC bought a new position in shares of Guardant Health during the third quarter valued at approximately $15,624,000. Cerity Partners LLC grew its stake in shares of Guardant Health by 54.6% in the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company's stock worth $4,473,000 after buying an additional 68,883 shares during the last quarter. Geode Capital Management LLC increased its position in Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock valued at $64,754,000 after buying an additional 29,686 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Guardant Health by 1,282.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock valued at $28,128,000 after buying an additional 1,137,482 shares during the last quarter. Finally, First Light Asset Management LLC boosted its holdings in Guardant Health by 119.7% in the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company's stock worth $12,042,000 after acquiring an additional 227,202 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Insider Transactions at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of the company's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now owns 2,676 shares of the company's stock, valued at $93,660. This represents a 46.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Meghan V. Joyce sold 2,896 shares of the business's stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,548 shares of company stock worth $179,782 in the last quarter. Company insiders own 5.50% of the company's stock.

Wall Street Analyst Weigh In

GH has been the subject of a number of recent research reports. Guggenheim restated a "buy" rating on shares of Guardant Health in a research note on Wednesday. The Goldman Sachs Group upped their target price on shares of Guardant Health from $32.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Sanford C. Bernstein dropped their price target on shares of Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 30th. JPMorgan Chase & Co. upped their price objective on Guardant Health from $48.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Finally, Leerink Partners lowered their target price on Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a research report on Thursday, October 17th. Fifteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $40.60.

Guardant Health Stock Up 4.6 %

Shares of NASDAQ GH traded up $2.07 during trading hours on Wednesday, hitting $47.20. 5,915,052 shares of the stock were exchanged, compared to its average volume of 2,793,457. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $49.86. The firm has a fifty day moving average price of $34.21 and a 200-day moving average price of $29.13. The company has a market cap of $5.83 billion, a PE ratio of -11.13 and a beta of 1.28.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. During the same quarter last year, the company earned ($0.73) EPS. The business's revenue was up 33.9% compared to the same quarter last year. As a group, equities analysts anticipate that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.